Mu-opioid receptor – delta-opioid receptor heteromer (MOR–DOR heteromer)

The **Mu-opioid receptor – delta-opioid receptor heteromer** is a molecular complex formed when individual mu-opioid receptors (MOR) and delta-opioid receptors (DOR), both members of the G protein-coupled receptor superfamily, physically associate to create a new functional entity. This heteromer exhibits distinct pharmacological properties, signaling mechanisms, and trafficking compared to the individual receptors: for example, ligand binding at one protomer may allosterically modulate the activity of its partner, and heteromer-selective ligands can induce unique intracellular signaling profiles such as enhanced calcium influx or altered β-arrestin recruitment[5][7]. Formation of these heteromers is dynamic and can be regulated by chronic opioid exposure, inflammation, and other physiological or pathological stimuli[3]. The MOR–DOR heteromer is being studied as a **therapeutic target** for developing **safer and more effective analgesics**, with the goal of exploiting its distinct functional properties to achieve pain relief with minimized risk of addiction and tolerance[2][5][7]. Selective drugs for this target—and especially bivalent ligands—may represent a novel strategy for opioid therapy, though challenges remain in targeting heteromers in vivo and minimizing side effects associated with opioid pharmacology[5][7].

Other names

MOR–DOR heterodimermu–delta opioid receptor heteromerMOR:DOR heteromerDOR-MOR heteromermu/delta-opioid receptor complex

Agonists that selectively bind to the heteromer may induce distinct signaling pathways, including altered G protein coupling (e.g., Gz, β-arrestin recruitment) Allosteric interactions: ligand binding at one receptor protomer modulates the affinity/function of the partner Bivalent ligands can bridge both receptors, modulating signaling, trafficking, and internalization Combined delta agonist/MOR antagonist approaches aim to enhance analgesia while reducing addictive side effects